LC-MS/MS is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Updated 2025-08-15. Numbers and descriptions here follow the published literature rather than marketing material.
A persistent misconception is that cardarine is a fat-burning drug or a safe alternative to anabolic steroids. No approved therapeutic product exists, and human safety data are limited. The tumor findings in rodents remain a central concern in scientific reviews. Products sold online may contain inaccurate labels, impurities, or different compounds entirely, which complicates any assessment of effects. Independent testing of such products has reported frequent mislabeling. For these reasons, discussions in the literature emphasize risks and unknowns rather than benefits.
Cardarine is not approved for human therapeutic use in any major jurisdiction. It appears on the World Anti-Doping Agency Prohibited List as a PPARδ agonist within the hormone and metabolic modulators category. Sports organizations test for it because it has been detected in athlete samples and seized products. Regulatory actions against marketed research chemical versions have occurred in several countries, though enforcement varies. Availability through unregulated channels complicates oversight.
Regulatory treatment varies, but cardarine is not approved as a medicine. Sports authorities list GW501516 as a prohibited substance, and it is banned at all times under the World Anti-Doping Agency code. Many countries restrict sales for human consumption, while online vendors market it as a research chemical. Such products may lack purity data, and their actual contents can differ from the label. Purchasing or possessing cardarine may carry legal consequences depending on jurisdiction. The compound is not a dietary supplement ingredient in regulated markets.
Clinical development stopped after rodent studies showed tumors at multiple sites. Whether those findings predict human cancer risk remains an open question, but they led sponsors to discontinue programs. Human safety data are limited to small, short-term studies that were not designed to assess cancer risk. Reported effects in those studies included changes in blood lipids, but the evidence is insufficient for medical use. Long-term consequences of nonmedical use are not well characterized. Questions about dose, duration, and individual susceptibility remain unresolved.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Not approved for human therapeutic use | No marketing authorization identified in major jurisdictions. |
| Anti-doping class | PPARδ agonist; hormone and metabolic modulators | Listed on the WADA Prohibited List. |
| Common test matrix | Urine | Also blood and tissue in research settings. |
| Typical analytical method | LC-MS/MS | Targets parent compound and metabolites. |
| Major safety signal | Tumor findings in rodents | Human relevance not established; limited human data. |
Laboratory studies indicate that GW501516 activates PPARδ, a nuclear receptor involved in fatty acid oxidation and energy metabolism. In rodent experiments, treated animals often showed increased endurance and reduced fat mass. These effects were observed under controlled conditions and do not establish safe or effective use in humans. The exact dose-response relationship in humans remains poorly characterized. Species differences in metabolism can affect how results translate across animals and people.
Safety concerns emerged from long-term animal studies. In rodents given the compound for extended periods, researchers found an increased incidence of certain cancers, including liver and bladder tumors. These findings contributed to the discontinuation of clinical development. Whether similar risks apply to short-term or low-level exposure in humans is not established, and controlled human safety data are limited. The relevance of high-dose rodent carcinogenicity findings to human use remains a subject of debate.
Stability of GW501516 depends on form, temperature, light exposure, and moisture. Solid reference material is typically stored frozen or refrigerated in a desiccator and protected from light. Solutions in organic solvents such as dimethyl sulfoxide are often kept frozen in aliquots to reduce freeze-thaw cycling. Aqueous solubility is low, so aqueous stock solutions can be difficult to prepare without cosolvents. Degradation may appear as changes in chromatographic purity or mass spectral signal. Stability studies are needed to establish shelf life for any specific preparation.
Quality assessment for cardarine samples usually combines identity, purity, and impurity testing. Nuclear magnetic resonance spectroscopy and mass spectrometry can confirm molecular structure, while high-performance liquid chromatography estimates purity. Certificates of analysis from testing laboratories may list these results, but they do not establish safety or legality. In the absence of approved manufacturing, products sold online may contain the wrong compound, variable amounts, or unlisted contaminants. Independent verification is therefore central to analytical work and to interpreting any reported biological activity.
Laboratory detection of GW501516 commonly uses liquid chromatography coupled with tandem mass spectrometry. The method can identify the parent compound or its metabolites in urine and blood after sample cleanup. Protein precipitation, solid-phase extraction, or enzymatic hydrolysis may precede analysis, depending on the matrix. Reference standards are required for accurate quantification and confirmation. Because the compound is not approved, testing often occurs in anti-doping, forensic, or research settings rather than routine clinical care. Results are reported with limits of detection and quantification.
Cardarine can be detected in biological samples and product materials using liquid chromatography coupled to tandem mass spectrometry (LC-MS/MS). The method separates compounds by chromatography and identifies them by mass-to-charge transitions, allowing low-level detection in urine or blood. Sample preparation often involves enzymatic hydrolysis, solid-phase extraction, or protein precipitation. Certified reference materials and isotope-labeled internal standards improve quantification. Detection windows depend on metabolism, matrix, and assay sensitivity, so no single universal window applies.
Regulatory treatment of cardarine differs by context and jurisdiction. In competitive sport, the World Anti-Doping Agency lists PPARδ agonists, including GW501516, as prohibited at all times. Outside sport, it lacks approval as a prescription medicine in major drug markets, and products sold for human consumption may be treated as unapproved drugs. Some countries also restrict importation or sale through general consumer protection and medicines laws. These classifications affect availability, testing, and legal risk without establishing therapeutic value.
Because cardarine is not an approved medicine, no pharmacopeial monograph defines its identity, purity, or storage requirements. Laboratories typically rely on in-house methods and reference standards when testing materials labeled as GW501516. Certificates of analysis may report purity and identity for a specific batch, but their scope varies and they do not guarantee safety or legal status. Independent verification can include high-performance liquid chromatography, mass spectrometry, nuclear magnetic resonance, and elemental analysis. The distinction between research chemical labeling and human use is significant because quality standards and oversight differ.
S. affinis is planted as a bulb (vegetative) in spring (March–May). Multiple bulbs are planted 5 to 8 cm (2 to 3+1⁄8 in) deep into a hole of dimensions 30 by 30 cm (12 by 12 in). The plant can achieve a height of 30 cm (12 in). Weeding is necessary but it is important not to damage the root system. A sufficient water supply during summer is important. Harvest is from November to March. It is important that the soil is not frozen when harvesting. The storage of S. affinis tubers is difficult. Because of their thin skin, they can be stored only for a few days, about a week in a fridge. An alternative can be a fresh ongoing harvesting out of humid sand, thereby the tubers stay fresh for several months.
==== Nonreversible couples ==== Many redox processes observed by CV are quasi-reversible or non-reversible. In such cases the thermodynamic potential E01/2 is often deduced by simulation. The irreversibility is indicated by ipa/ipc ≠ 1. Deviations from unity are attributable to a subsequent chemical reaction that is triggered by the electron transfer. Such EC processes can be complex, involving isomerization, dissociation, association, etc.
Motif discovery happens in three major phases. A pre-processing stage where sequences are meticulously prepared in assembly and cleaning steps. Assembly involves selecting sequences that contain the desired motif in large quantities, and extraction of unwanted sequences using clustering. Cleaning then ensures the removal of any confounding elements. Next there is the discovery stage. In this phase sequences are represented using consensus strings or Position-specific Weight Matrices (PWM). After motif representation, an objective function is chosen and a suitable search algorithm is applied to uncover the motifs. Finally the post-processing stage involves evaluating the discovered motifs.
=== Tolerance === A very rapid and strong tolerance, known as tachyphylaxis, develops to the effects of psychedelics with repeated administration. It develops with a single dose and is present within hours to days. Already by the second day, with LSD, there was a 50% decrease in psychoactive effects in one study. Following a few days of repeated administration, or 3 to 4 days in the case of LSD, there is an almost complete absence of effects. The tolerance remains stable thereafter. In one study that gave LSD continuously for up to 84 days, doubling, tripling, and quadrupling the dose was unable to fully overcome the tolerance and restore effects. An abstinence period of 3 to 6 days is required for sensitivity to return and tolerance to fully reset. LSD, psilocybin, and mescaline all show cross-tolerance with each other. Tolerance has been shown to develop to numerous psychedelics in animals and/or humans. Tolerance with psychedelics develops to both their psychoactive effects and their physical effects, such as pupil dilation and tachycardia. As a result of the tolerance, recreational psychedelic users do not use the drugs daily but often show a once-per-week use pattern. Some possible exceptions among psychedelics which may not build tolerance or may develop it much less rapidly include dimethyltryptamine (DMT), ayahuasca (which contains DMT), and 5-MeO-DMT. Similarly, the structurally related dipropyltryptamine (DPT) and diisopropyltryptamine (DiPT) did not show behavioral tolerance in rodents, in contrast to DOI and 2C-T-7.
Sources: en.wikipedia.org
Many herbs are applied topically to the skin in a variety of forms. Essential oil extracts can be applied to the skin, usually diluted in a carrier oil. Many essential oils can burn the skin or are simply too high dose used straight; diluting them in olive oil or another food grade oil such as almond oil can allow these to be used safely as a topical. Salves, oils, balms, creams, and lotions are other forms of topical delivery mechanisms. Most topical applications are oil extractions of herbs. Taking a food-grade oil and soaking herbs in it for anywhere from weeks to months allows certain phytochemicals to be extracted into the oil. This oil can then be made into salves, creams, lotions, or simply used as an oil for topical application. Many massage oils, antibacterial salves, and wound healing compounds are made this way. Inhalation, as in aromatherapy, can be used as a treatment.
The two substrates of this enzyme are [tryptophol and oxidised nicotinamide adenine dinucleotide phosphate (NADP+). Its products are indole-3-acetaldehyde, reduced NADPH, and a proton. This enzyme belongs to the family of oxidoreductases, specifically those acting on the CH-OH group of donor with NAD+ or NADP+ as acceptor. The systematic name of this enzyme class is (indol-3-yl)ethanol:NADP+ oxidoreductase. Other names in common use include indoleacetaldehyde (reduced nicotinamide adenine dinucleotide, phosphate) reductase, indole-3-acetaldehyde reductase (NADPH), and indole-3-ethanol:NADP+ oxidoreductase. This enzyme participates in tryptophan metabolism.
SUMOplot Analysis Program — predicts and scores SUMOylation sites in your protein (by Abgent) seeSUMO - prediction of SUMOylation sites SUMOsp - prediction of SUMOylation sites JASSA - Predicts and scores SUMOylation sites and SIM (SUMO interacting motif)
Sources: en.wikipedia.org
No. Cardarine has not received approval for human therapeutic use in major jurisdictions. It remains an investigational compound.
It is classified as a PPARδ agonist on the WADA Prohibited List. Anti-doping laboratories can detect it and its metabolites in urine. Its use is banned in competition and usually out of competition.
Rodent studies reported increased tumor incidence at multiple sites. The human relevance remains uncertain, but the findings contributed to discontinuation of development. No long-term human cancer data are available.
No. Cardarine is GW501516, a PPARδ agonist, while SARMs act on androgen receptors. The two classes are often grouped in informal discussions despite different mechanisms.